| Code | CSB-RA023984MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to atenastobart, designed to target TNFRSF9 (tumor necrosis factor receptor superfamily member 9), also known as 4-1BB or CD137. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a critical role in enhancing T cell proliferation, survival, and effector function. Upon binding with its ligand 4-1BBL, TNFRSF9 delivers potent costimulatory signals that amplify cellular immune responses. This receptor has emerged as a significant target in immuno-oncology research due to its ability to promote anti-tumor immunity and enhance T cell-mediated cytotoxicity against malignant cells.
Atenastobart is an investigational agonistic antibody developed to stimulate TNFRSF9 signaling, thereby enhancing immune responses against cancer. This biosimilar provides researchers with a valuable tool for investigating TNFRSF9-mediated immune activation, studying T cell costimulation mechanisms, and exploring combination immunotherapy strategies in preclinical cancer models. It supports investigations into tumor immunology, immune checkpoint modulation, and cellular immune response enhancement.
There are currently no reviews for this product.